MX2013001906A - Metodos para reducir la concentracion de lactato en la sangre. - Google Patents

Metodos para reducir la concentracion de lactato en la sangre.

Info

Publication number
MX2013001906A
MX2013001906A MX2013001906A MX2013001906A MX2013001906A MX 2013001906 A MX2013001906 A MX 2013001906A MX 2013001906 A MX2013001906 A MX 2013001906A MX 2013001906 A MX2013001906 A MX 2013001906A MX 2013001906 A MX2013001906 A MX 2013001906A
Authority
MX
Mexico
Prior art keywords
methods
reducing blood
lactate concentration
blood lactate
concentration
Prior art date
Application number
MX2013001906A
Other languages
English (en)
Inventor
Jeffrey J Zachwieja
Mark Arthur Pirner
Johneric William Smith
Original Assignee
Stokely Van Camp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stokely Van Camp Inc filed Critical Stokely Van Camp Inc
Publication of MX2013001906A publication Critical patent/MX2013001906A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means
    • G01N33/48728—Investigating individual cells, e.g. by patch clamp, voltage clamp
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La presente invención se dirige a métodos para reducir la concentración de lactato en la sangre durante el ejercicio, actividad física o desempeño atlético.
MX2013001906A 2010-09-17 2011-09-12 Metodos para reducir la concentracion de lactato en la sangre. MX2013001906A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38397310P 2010-09-17 2010-09-17
US201161498007P 2011-06-17 2011-06-17
PCT/US2011/051207 WO2012037023A1 (en) 2010-09-17 2011-09-12 Methods of reducing blood lactate concentration

Publications (1)

Publication Number Publication Date
MX2013001906A true MX2013001906A (es) 2013-07-05

Family

ID=44678051

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001906A MX2013001906A (es) 2010-09-17 2011-09-12 Metodos para reducir la concentracion de lactato en la sangre.

Country Status (10)

Country Link
US (4) US9198453B2 (es)
EP (1) EP2615931A1 (es)
JP (1) JP2013542924A (es)
CN (1) CN103096737A (es)
AU (1) AU2011302390B2 (es)
BR (1) BR112013005810A2 (es)
CA (1) CA2808530A1 (es)
MX (1) MX2013001906A (es)
WO (1) WO2012037023A1 (es)
ZA (1) ZA201301234B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013542924A (ja) * 2010-09-17 2013-11-28 ストークリー−ヴァン キャンプ インコーポレイテッド 血中乳酸濃度を減少させる方法
KR101454425B1 (ko) 2012-10-11 2014-11-03 포항공과대학교 산학협력단 미리세틴을 유효성분으로 포함하는 운동수행능력 증강용 조성물
JP6101060B2 (ja) * 2012-11-30 2017-03-22 上野製薬株式会社 終末糖化産物生成抑制剤
US20140199432A1 (en) * 2012-12-05 2014-07-17 Richard Alexander SCHMOTTER Alkaline compositions
US9072316B2 (en) * 2012-12-05 2015-07-07 Richard Alexander SCHMOTTER Alkaline compositions
US11291392B2 (en) 2014-03-03 2022-04-05 LifeQ Limited Limited Real-time and continuous determination of excess post-exercise oxygen consumption and the estimation of blood lactate
WO2016108056A1 (en) * 2014-12-30 2016-07-07 Lifeq Global Limited A ppg-based physiological sensing system with a spatio-temporal sampling approach towards identifying and removing motion artifacts from optical signals
TWI583388B (zh) 2016-08-24 2017-05-21 國立體育大學 胚芽乳酸桿菌用於製備改善運動表現及降低肌肉疲勞之益生菌組合物之用途
WO2019043846A1 (ja) * 2017-08-30 2019-03-07 大塚製薬株式会社 ケンペロール類縁体含有組成物
CA3082369A1 (en) * 2017-12-04 2019-06-13 The General Hospital Corporation Extracellular redox enzyme system to alleviate disease
KR101979016B1 (ko) * 2017-12-22 2019-05-15 선문대학교 산학협력단 곤충 단백질을 포함하는 운동기능 개선용 식품 조성물
JPWO2020175579A1 (ja) 2019-02-27 2021-12-23 大塚製薬株式会社 植物由来エキス及び／又は植物由来加工品含有組成物
WO2022269931A1 (ja) * 2021-06-25 2022-12-29 大塚製薬株式会社 筋損傷抑制用組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07196523A (ja) * 1994-01-07 1995-08-01 Oomiya Yakugyo Kk ケルセチン配糖体を含有する内用液剤
US6224872B1 (en) * 1997-07-31 2001-05-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Composition
DE60124099T2 (de) * 2000-06-20 2007-06-06 Calpis Co., Ltd. Saures milchgetraenk
JP4390428B2 (ja) 2001-05-01 2009-12-24 株式会社林原生物化学研究所 含カルシウム組織強化剤
WO2003092666A1 (fr) 2002-05-01 2003-11-13 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agents de renforcement de tissus contenant du calcium et utilisation correspondante
US20040126461A1 (en) 2002-10-23 2004-07-01 Lines Thomas Christian Composition for enhancing physical performance
CN100361599C (zh) * 2002-10-23 2008-01-16 克尔塞根控股有限公司 抗氧化组合物
ES2322577T3 (es) * 2002-10-23 2009-06-23 Quercegen Holdings Llc Composiciones antioxidantes.
US20060210623A1 (en) * 2005-03-17 2006-09-21 Stach Paul E Sustained release delivery of isradipine
US20090214712A1 (en) * 2008-02-21 2009-08-27 The Coca Cola Company Milk-Based Beverage and Method for Preventing Off-Flavors in a Milk-Based Beverage
CN101336978B (zh) * 2008-08-12 2013-01-30 西北农林科技大学 一种北枳椇总黄酮的提取方法
US20100196577A1 (en) * 2009-02-03 2010-08-05 Tropicana Products, Inc. Microencapsulated citrus phytochemicals comprising citrus limonoids and application to sports drinks
CN101536803A (zh) * 2009-04-23 2009-09-23 郑鉴忠 荞麦芦丁饮料生产方法
AU2010282697A1 (en) * 2009-08-10 2012-03-15 Stokely-Van Camp, Inc. Method for preparing a flavonoid slurry
JP2013542924A (ja) * 2010-09-17 2013-11-28 ストークリー−ヴァン キャンプ インコーポレイテッド 血中乳酸濃度を減少させる方法

Also Published As

Publication number Publication date
US9198453B2 (en) 2015-12-01
CA2808530A1 (en) 2012-03-22
CN103096737A (zh) 2013-05-08
AU2011302390A1 (en) 2013-02-28
AU2011302390B2 (en) 2014-08-07
US20120077873A1 (en) 2012-03-29
US10130607B2 (en) 2018-11-20
US20170281590A1 (en) 2017-10-05
BR112013005810A2 (pt) 2016-05-10
JP2013542924A (ja) 2013-11-28
US9693991B2 (en) 2017-07-04
US20170290798A1 (en) 2017-10-12
ZA201301234B (en) 2014-04-30
US10105344B2 (en) 2018-10-23
EP2615931A1 (en) 2013-07-24
US20160151327A1 (en) 2016-06-02
WO2012037023A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
MX2013001906A (es) Metodos para reducir la concentracion de lactato en la sangre.
HK1214168A1 (zh) 通過控制血糖水平用於治療糖尿病及相關疾病的組合物、方法以及用途
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
MX2013000301A (es) Factores quimericos de coagulacion.
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
PH12014501702A1 (en) Imidazopyrrolidinone compounds
EA201391019A1 (ru) Соединения и способы для модуляции киназ, а также показания к их применению
EA201290988A1 (ru) Стереоселективный синтез фосфорсодержащих активных соединений
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
EA201491028A1 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
PH12014502513A1 (en) Nampt inhibitors
MX2014013752A (es) Inhibidores de nampt.
EA201200999A1 (ru) Способы лечения рака молочной железы
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
MX350282B (es) Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas.
MX348311B (es) Inhibidores nampt.
EA201201296A1 (ru) Способы лечения диабетических язв стопы
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
EP2663193A4 (en) CARBON MONOXIDE SOLUTION FOR THE TREATMENT OF DISEASES, INCLUDING SICKLE LENGTH
WO2012018866A3 (en) Methods and compositions for the diagnosis and treatment of breast cancer
WO2012145399A3 (en) Methods of diagnosing cancer in a patient
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
EA201401277A1 (ru) Соединения метантиона, обладающие противовирусной активностью
EA201400911A1 (ru) Осветляющая кожу композиция
EA201390532A1 (ru) Композиции сульфамидых ингибиторов ns3, содержащие витамин е

Legal Events

Date Code Title Description
FA Abandonment or withdrawal